NCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
Clinical Trials
41 trialsNCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
NCT05765812 2026-02-27
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Phase 1/2 Recruiting
NCT05124912 2026-02-20
REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
Phase NA Recruiting
NCT03423628 2025-12-22
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
Phase 1 Recruiting
NCT04373785 2025-10-21
NG101m Adjuvant Therapy in Glioblastoma Patients
NeuGATE Theranostics
Phase 1/2 Not yet recruiting
NCT01107522 2025-09-09
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With TemodarĀ® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With TemodarĀ® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Tactical Therapeutics, Inc.
Phase 1 Unknown
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT03250299 2024-06-24
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Basilea Pharmaceutica
Phase 1 Terminated
NCT03776071 2024-04-22
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC
Phase 3 Completed
NCT02880410 2024-04-12
FLAG
Monteris Medical
Phase 1 Terminated
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT03867123 2023-02-21
A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
Laminar Pharmaceuticals
Phase 1 Completed
NCT00005887 2021-08-23
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02903069 2021-04-19
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
Phase 1 Completed
NCT00402116 2020-08-06
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Eli Lilly and Company
Phase 1/2 Completed
NCT01390948 2020-08-06
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
Hoffmann-La Roche
Phase 2 Completed
NCT01790503 2020-06-30
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Daiichi Sankyo
Phase 1/2 Completed
NCT02799238 2020-04-30
ALECSAT
CytoVac A/S
Phase 2 Completed
NCT00977431 2019-02-18
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
Boehringer Ingelheim
Phase 1 Completed
NCT03780569 2018-12-20
TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
NovoCure Ltd.
Phase NA Unknown
NCT01860638 2018-04-30
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
NCT02254954 2018-02-27
Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma
Actelion
Phase 1 Terminated
NCT00943826 2017-09-25
A Study of Bevacizumab (AvastinĀ®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed
NCT00686725 2017-06-14
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00684567 2017-06-07
Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00813943 2017-01-30
CORE
EMD Serono
Phase 2 Completed
NCT00705198 2016-11-15
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
Merck Sharp & Dohme LLC
Completed
NCT00267592 2016-05-19
Safety and Efficacy of Talampanel in Glioblastoma Multiforme
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT01213407 2016-05-19
GBM-Vax
Activartis Biotech
Phase 2 Completed
NCT00704808 2015-09-09
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Merck Sharp & Dohme LLC
Completed
NCT00725010 2015-09-09
Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
Merck Sharp & Dohme LLC
Completed
NCT00723827 2015-01-30
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Merck Sharp & Dohme LLC
Completed
NCT00960492 2014-09-22
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
Exelixis
Phase 1 Completed
NCT01516983 2014-02-17
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT01285414 2012-04-11
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
Myrexis Inc.
Phase 2 Completed
NCT00089427 2011-07-04
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00615186 2011-02-10
Glass-Art
Bradmer Pharmaceuticals Inc.
Phase 3 Terminated
NCT00768911 2010-10-27
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
Adnexus, A Bristol-Myers Squibb R&D Company
Phase 1 Unknown